Investigating the Genetic Etiology of Pediatric Patients with Peripheral Hypotonia Using the Next-Generation Sequencing Method

Abstract

Background Hypotonia occurs as a result of neurological dysfunction in the brain, brainstem, spinal cord, motor neurons, anterior horn cells, peripheral nerves, and muscles. Although the genotype–phenotype correlation can be established in 15 to 30% of patients, it is difficult to obtain a correlation in most cases.

Aims This study was aimed to investigate the genetic etiology in cases of peripheral hypotonia that could not be diagnosed using conventional methods.

Methods A total of 18 pediatric patients with peripheral hypotonia were included. They were referred to our genetic disorders diagnosis center from the Pediatric Neurology Department with a prediagnosis of hypotonia. A custom designed multigene panel, including ACTA1, CCDC78, DYNC1H1, GARS, RYR1, COL6A1, COL6A2, COL6A3, FKRP, FKTN, IGHMBP2, LMNA, LAMA2, LARGE1, MTM1, NEM, POMGnT1, POMT1, POMT2, and SEPN1, was used for genetic analysis using next-generation sequencing (NGS).

Results In our study, we found 13 variants including pathogenic (two variants in LAMA2) and likely pathogenic variants (three variants in RYR1 and POMGnT1) and variants of uncertain clinical significance (eight variants in RYR1, COL6A3, COL6A2, POMGnT1 and POMT1) in 11 (61%) out of 18 patients. In one of our patients, a homozygous, likely pathogenic c.1649G > A, p.(Ser550Asn) variant was defined in the POMGnT1 gene which was associated with a muscle–eye–brain disease phenotype.

Conclusion The contribution of an in-house designed gene panel in the etiology of peripheral hypotonia with a clinical diagnosis was 5.5%. An important contribution with the clinical diagnosis can be made using the targeted multigene panels in larger samples.

Keywords

hypotonia - peripheral hypotonia - next-generation sequencing - genetic etiology - multigene panel

Authors' Contributions

D.E. devised the project, the main conceptual ideas, and worked the technical details. D.E. and H.G. conceived the study and were in charge of overall direction and planning. Y.K., H.G., S.T.K., and S.Y. followed-up the patients. D.E., H.G., S.D., and E.A. contributed to the analysis and interpretation of the study. All authors approved and contributed to the final version of the manuscript.

Publikationsverlauf

Artikel online veröffentlicht:
15. Juli 2022

• References

• 1 Bayram E, Yiş U, Kurul S. Hypotonic infant: clinical and etiological evaluation. DAE 2012; 26 (03) 219-228
• 2 Lisi EC, Cohn RD. Genetic evaluation of the pediatric patient with hypotonia: perspective from a hypotonia specialty clinic and review of the literature. Dev Med Child Neurol 2011; 53 (07) 586-599
• 3 Peredo DE, Hannibal MC. The floppy infant: evaluation of hypotonia. Pediatr Rev 2009; 30 (09) e66-e76
• 4 Sparks SE. Neonatal hypotonia. Clin Perinatol 2015; 42 (02) 363-371 , ix
• 5 Prasad AN, Prasad C. Genetic evaluation of the floppy infant. Semin Fetal Neonatal Med 2011; 16 (02) 99-108
• 6 D'Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy. Orphanet J Rare Dis 2011; 6: 71
• 7 Wang Y, Peng W, Guo HY. et al. Next-generation sequencing-based molecular diagnosis of neonatal hypotonia in Chinese Population. Sci Rep 2016; 6: 29088
• 8 Chae JH, Vasta V, Cho A. et al. Utility of next generation sequencing in genetic diagnosis of early onset neuromuscular disorders. J Med Genet 2015; 52 (03) 208-216
• 9 Vasli N, Böhm J, Le Gras S. et al. Next generation sequencing for molecular diagnosis of neuromuscular diseases. Acta Neuropathol 2012; 124 (02) 273-283
• 10 Kitamura Y, Kondo E, Urano M, Aoki R, Saito K. Target resequencing of neuromuscular disease-related genes using next-generation sequencing for patients with undiagnosed early-onset neuromuscular disorders. J Hum Genet 2016; 61 (11) 931-942
• 11 Gonzalez-Quereda L, Rodriguez MJ, Diaz-Manera J. et al. Targeted next-generation sequencing in a large cohort of genetically undiagnosed patients with neuromuscular disorders in Spain. Genes (Basel) 2020; 11 (05) 539
• 12 Karczewski KJ, Francioli LC, Tiao G. et al; Genome Aggregation Database Consortium. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 2020; 581 (7809): 434-443
• 13 Schwarz JM, Rödelsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods 2010; 7 (08) 575-576
• 14 Adzhubei IA, Schmidt S, Peshkin L. et al. A method and server for predicting damaging missense mutations. Nat Methods 2010; 7 (04) 248-249
• 15 Sim NL, Kumar P, Hu J, Henikoff S, Schneider G, Ng PC. SIFT web server: predicting effects of amino acid substitutions on proteins. Nucleic Acids Res 2012; 40 (Web Server issue): W452-7
• 16 Quang D, Chen Y, Xie X. DANN: a deep learning approach for annotating the pathogenicity of genetic variants. Bioinformatics 2015; 31 (05) 761-763
• 17 Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res 2019; 47 (D1) D886-D894
• 18 Davydov EV, Goode DL, Sirota M, Cooper GM, Sidow A, Batzoglou S. Identifying a high fraction of the human genome to be under selective constraint using GERP++. PLOS Comput Biol 2010; 6 (12) e1001025
• 19 Richards S, Aziz N, Bale S. et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17 (05) 405-424
• 20 Paro-Panjan D, Neubauer D. Congenital hypotonia: is there an algorithm?. J Child Neurol 2004; 19 (06) 439-442
• 21 Laugel V, Cossée M, Matis J. et al. Diagnostic approach to neonatal hypotonia: retrospective study on 144 neonates. Eur J Pediatr 2008; 167 (05) 517-523
• 22 Birdi K, Prasad AN, Prasad C, Chodirker B, Chudley AE. The floppy infant: retrospective analysis of clinical experience (1990-2000) in a tertiary care facility. J Child Neurol 2005; 20 (10) 803-808
• 23 Richer LP, Shevell MI, Miller SP. Diagnostic profile of neonatal hypotonia: an 11-year study. Pediatr Neurol 2001; 25 (01) 32-37
• 24 Warman Chardon J, Beaulieu C, Hartley T, Boycott KM, Dyment DA. Axons to exons: the molecular diagnosis of rare neurological diseases by next-generation sequencing. Curr Neurol Neurosci Rep 2015; 15 (09) 64
• 25 Özaydın E, Ürey T, Gündüz M, Güven A, Köse G. Hipotonik infantların ayırıcı tanısında algoritma faydalı mıdır? 53 Olgunun Değerlendirilmesi. Turkish J Pediatr Dis. 2013; 3: 128-133
• 26 Davis MR, Haan E, Jungbluth H. et al. Principal mutation hotspot for central core disease and related myopathies in the C-terminal transmembrane region of the RYR1 gene. Neuromuscul Disord 2003; 13 (02) 151-157
• 27 Amburgey K, Bailey A, Hwang JH. et al. Genotype-phenotype correlations in recessive RYR1-related myopathies. Orphanet J Rare Dis 2013; 8: 117
• 28 Uribe ML, Haro C, Ventero MP, Campello L, Cruces J, Martín-Nieto J. Expression pattern in retinal photoreceptors of POMGnT1, a protein involved in muscle-eye-brain disease. Mol Vis 2016; 22: 658-673
• 29 Yiş U, Uyanik G, Rosendahl DM. et al. Clinical, radiological, and genetic survey of patients with muscle-eye-brain disease caused by mutations in POMGNT1. Pediatr Neurol 2014; 50 (05) 491-497
• 30 Demir E, Gucuyener K, Akturk A. et al. An unusual presentation of muscle-eye-brain disease: severe eye abnormalities with mild muscle and brain involvement. Neuromuscul Disord 2009; 19 (10) 692-695
• 31 Endo T, Manya H, Seta N, Guicheney P. POMGnT1, POMT1, and POMT2 mutations in congenital muscular dystrophies. Methods Enzymol 2010; 479: 343-352
• 32 Yoshida A, Kobayashi K, Manya H. et al. Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev Cell 2001; 1 (05) 717-724
• 33 Taniguchi K, Kobayashi K, Saito K. et al. Worldwide distribution and broader clinical spectrum of muscle-eye-brain disease. Hum Mol Genet 2003; 12 (05) 527-534
• 34 Bönnemann CG. The collagen VI-related myopathies Ullrich congenital muscular dystrophy and Bethlem myopathy. Handb Clin Neurol 2011; 101: 81-96
• 35 Lee JH, Shin HY, Park HJ, Kim SH, Kim SM, Choi YC. Clinical, pathologic, and genetic features of collagen VI-related myopathy in Korea. J Clin Neurol 2017; 13 (04) 331-339
• 36 Briñas L, Richard P, Quijano-Roy S. et al. Early onset collagen VI myopathies: genetic and clinical correlations. Ann Neurol 2010; 68 (04) 511-520
• 37 Fan Y, Liu A, Wei C. et al. Genetic and clinical findings in a Chinese cohort of patients with collagen VI-related myopathies. Clin Genet 2018; 93 (06) 1159-1171
• 38 Peat RA, Baker NL, Jones KJ, North KN, Lamandé SR. Variable penetrance of COL6A1 null mutations: implications for prenatal diagnosis and genetic counselling in Ullrich congenital muscular dystrophy families. Neuromuscul Disord 2007; 17 (07) 547-557